BridgeMD
Danish trial of beta blocker treatment after myocardial infarction without reduced ejection fraction (DANBLOCK)
EU CTIS ID: 2024-515748-22-01
What this study is testing
The composite outcome of recurrent MI, all-cause mortality, revascularization with percutaneous coronary intervention or coronary artery bypass graft, ischemic stroke, incident heart failure, malignant ventricular arrhythmia or resuscitated cardiac arrest.
- Therapeutic confirmatory (Phase III)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- 18 years or older
- Left ventricular ejection fraction (LVEF) > 40%
- Myocardial infarction (MI) - The diagnosis of acute MI must meet the Universal ESC definition of MI40: Detection of a rise and/or fall of cardiac biomarker values with at least one value above the 99th percentile upper reference limit and with at least one of the followings: Symptoms of ischaemia, New or presumed new significant ST-segment–T wave (ST–T) changes or new left bundle branch block (LBBB), Development of pathological Q waves in the ECG, Imaging evidence of new loss of viable myocardium or new regional wall motion abnormality.
You likely can't join if
- Clinical evidence of heart failure at the time of discharge
- Pregnancy or of child bearing age not using safe anticonception
- Signed informed consent and expected cooperation during follow-up Any medical condition where BB treatment is indicated according to the treating physician, which may include: BB treated arrhythmias, BB treated hypertension, Cardiomyopathies, Seriously limited life-expectancy, Any condition (i.e. dementia) that could lead to increased risk for the patient when treated with BB-therapy Any contraindication to BB treatment according to the treating physician, which may include: Hypotension, Bradyarrhythmias, Severe peripheral artery disease, History of not able to tolerate BB-therapy, Severe COPD, Severe valvular heart disease
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.